Verastem Oncology Cancer Drug Combination Gets FDA Approval

Dow Jones

2025/05/09

By Josh Beckerman

Verastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ovarian cancer.

The company expects a combination co-pack will be available in the U.S. in about a week.

The approval was in advance of the June 30 Prescription Drug User Fee Act action date.

Verastem shares were flat at $6.69 prior to a trading halt for pending news.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

By Josh Beckerman

Verastem Oncology said the Food and Drug Administration approved the combination of Avmapki capsules and Fakzynja tablets for certain ovarian-cancer patients.

The company said Thursday it expects the combination co-pack of Avmapki and Fakzynja--or avutometinib and defactinib, respectively--will be available in the U.S. in about a week, marking its transition into a commercial-stage company.

Verastem previously said it was preparing for a mid-2025 launch. The FDA's approval was in advance of the June 30 Prescription Drug User Fee Act action date.

The Needham, Mass., company's shares, flat at $6.69 prior to a trading halt for pending news, spiked to $8 but were recently up 3.5%, to $6.93. The stock is up about 34% this year.

Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said. Verastem said it is conducting a confirmatory Phase 3 trial, RAMP 301.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

May 08, 2025 14:59 ET (18:59 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2534525091"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534525091\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534525091?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-09 01:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534525091","market":"other","top_or_hot":-1,"title":"Verastem Oncology Cancer Drug Combination Gets FDA Approval","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ovarian cancer. \n</p>\n<p>\n  The company expects a combination co-pack will be available in the U.S. in about a week. \n</p>\n<p>\n  The approval was in advance of the June 30 Prescription Drug User Fee Act action date. \n</p>\n<p>\n  Verastem shares were flat at $6.69 prior to a trading halt for pending news. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Verastem Oncology said the Food and Drug Administration approved the combination of Avmapki capsules and Fakzynja tablets for certain ovarian-cancer patients. \n</p>\n<p>\n  The company said Thursday it expects the combination co-pack of Avmapki and Fakzynja--or avutometinib and defactinib, respectively--will be available in the U.S. in about a week, marking its transition into a commercial-stage company. \n</p>\n<p>\n  Verastem previously said it was preparing for a mid-2025 launch. The FDA's approval was in advance of the June 30 Prescription Drug User Fee Act action date. \n</p>\n<p>\n  The Needham, Mass., company's shares, flat at $6.69 prior to a trading halt for pending news, spiked to $8 but were recently up 3.5%, to $6.93. The stock is up about 34% this year. \n</p>\n<p>\n  Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said. Verastem said it is conducting a confirmatory Phase 3 trial, RAMP 301. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2025 14:59 ET (18:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Oncology Cancer Drug Combination Gets FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Oncology Cancer Drug Combination Gets FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-09 01:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ovarian cancer. \n</p>\n<p>\n  The company expects a combination co-pack will be available in the U.S. in about a week. \n</p>\n<p>\n  The approval was in advance of the June 30 Prescription Drug User Fee Act action date. \n</p>\n<p>\n  Verastem shares were flat at $6.69 prior to a trading halt for pending news. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Verastem Oncology said the Food and Drug Administration approved the combination of Avmapki capsules and Fakzynja tablets for certain ovarian-cancer patients. \n</p>\n<p>\n  The company said Thursday it expects the combination co-pack of Avmapki and Fakzynja--or avutometinib and defactinib, respectively--will be available in the U.S. in about a week, marking its transition into a commercial-stage company. \n</p>\n<p>\n  Verastem previously said it was preparing for a mid-2025 launch. The FDA's approval was in advance of the June 30 Prescription Drug User Fee Act action date. \n</p>\n<p>\n  The Needham, Mass., company's shares, flat at $6.69 prior to a trading halt for pending news, spiked to $8 but were recently up 3.5%, to $6.93. The stock is up about 34% this year. \n</p>\n<p>\n  Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said. Verastem said it is conducting a confirmatory Phase 3 trial, RAMP 301. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2025 14:59 ET (18:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VSTM","symbol_name":"Verastem","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2534525091","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534525091","pubTimestamp":1746725940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Verastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ovarian cancer.The company expects a combination co-pack will be available in the U.S. in about a week.The approval was in advance of the June 30 Prescription Drug User Fee Act action date.Verastem shares were flat at $6.69 prior to a trading halt for pending news.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VSTM":"Verastem","BK4139":"生物科技"},"translate_title":"Verastem Oncology癌症药物组合获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1},"content_text":"By Josh Beckerman \n\n\n \n\n\nVerastem Oncology said the Food and Drug Administration approved the combination of avutometinib capsules and defactinib tablets for certain patients with KRAS-mutated recurrent low-grade serous ovarian cancer. \n\n\n  The company expects a combination co-pack will be available in the U.S. in about a week. \n\n\n  The approval was in advance of the June 30 Prescription Drug User Fee Act action date. \n\n\n  Verastem shares were flat at $6.69 prior to a trading halt for pending news. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n\n \n\n\n  By Josh Beckerman \n\n\n \n\n\n  Verastem Oncology said the Food and Drug Administration approved the combination of Avmapki capsules and Fakzynja tablets for certain ovarian-cancer patients. \n\n\n  The company said Thursday it expects the combination co-pack of Avmapki and Fakzynja--or avutometinib and defactinib, respectively--will be available in the U.S. in about a week, marking its transition into a commercial-stage company. \n\n\n  Verastem previously said it was preparing for a mid-2025 launch. The FDA's approval was in advance of the June 30 Prescription Drug User Fee Act action date. \n\n\n  The Needham, Mass., company's shares, flat at $6.69 prior to a trading halt for pending news, spiked to $8 but were recently up 3.5%, to $6.93. The stock is up about 34% this year. \n\n\n  Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said. Verastem said it is conducting a confirmatory Phase 3 trial, RAMP 301. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2025 14:59 ET (18:59 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}